The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile
Boustany A, Feuerstadt P, Tillotson G. The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile. Advances In Therapy 2024, 41: 3982-3995. PMID: 39276186, PMCID: PMC11480130, DOI: 10.1007/s12325-024-02972-0.Peer-Reviewed Original ResearchIncreased risk of C. difficile infectionRisk of C. difficile infectionClasses of antidepressantsClostridioides difficile infectionNovel treatment optionsPatients' quality of lifeMicrobiome-related factorsDevelopment of dysbiosisOpportunistic infectionsRecurrent CDIGut microbiomeRecurrence rateAntidepressant useDifficile infectionMental disordersTreatment optionsLive biotherapeutic productsComplex pathophysiologyIncreased riskC. difficileGut dysbiosisQuality of lifePatients' qualitySignificant healthcare concernAntidepressantsIntegrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, Khanna S, Berenson C, Wang E, Cohen S, Korman L, Lee C, Kelly C, Odio A, Cook P, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi D, Hasson B, McGovern B, von Moltke L, Pardi D. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infectious Diseases And Therapy 2024, 13: 2105-2121. PMID: 38941068, PMCID: PMC11416444, DOI: 10.1007/s40121-024-01007-z.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsPhase 3 trialRCDI rateAnalysis of treatment-emergent adverse eventsTreatment-related treatment-emergent adverse eventsStandard-of-care antibioticsHigh-risk patientsClostridioides difficile infectionPreventing rCDIRenal impairment/failureAbdominal painRecurrent CDIEfficacy analysisAdverse eventsTreatment-relatedPrevent recurrencePrevalent comorbiditiesRCDIWeeksAntibioticsPatientsComorbiditiesEfficacyPlaceboMicrobiome